1. Home
  2. SXI vs NAMS Comparison

SXI vs NAMS Comparison

Compare SXI & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Standex International Corporation

SXI

Standex International Corporation

HOLD

Current Price

$328.07

Market Cap

3.5B

Sector

Industrials

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$34.72

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SXI
NAMS
Founded
1955
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
4.1B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
SXI
NAMS
Price
$328.07
$34.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$289.67
$46.75
AVG Volume (30 Days)
219.6K
1.1M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
0.54%
N/A
EPS Growth
N/A
N/A
EPS
6.98
N/A
Revenue
$604,535,000.00
N/A
Revenue This Year
$14.87
$17.96
Revenue Next Year
$6.07
$540.65
P/E Ratio
$49.92
N/A
Revenue Growth
N/A
N/A
52 Week Low
$152.64
$20.53
52 Week High
$363.89
$42.21

Technical Indicators

Market Signals
Indicator
SXI
NAMS
Relative Strength Index (RSI) 58.60 60.15
Support Level $217.86 $33.83
Resistance Level N/A $37.27
Average True Range (ATR) 15.05 1.53
MACD 1.82 0.56
Stochastic Oscillator 49.47 76.74

Price Performance

Historical Comparison
SXI
NAMS

About SXI Standex International Corporation

Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. The company has five reportable segments: Electronics, Engraving, Scientific, Engineering Technologies, and Specialty Solutions. The maximum revenue is generated from its Electronics segment, which is a component and value-added services provider of both sensing and switching technologies, as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging, among others. Geographically, it derives key revenue from the United States and the rest from the Asia Pacific, Europe, the Middle East, and Africa (EMEA), as well as other regions.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: